HUMA

Humacyte, Inc.

Price Chart

Latest Quote

$0.70

-0.00 (-0.39%)

Current Price

Previous Close	$0.70
Open	$0.74
Day High	$0.77
Day Low	$0.64
Volume	29,444,660

Fetched: 2026-06-25T02:45:57

Stock Information

Shares Outstanding	269.64M
Total Debt	$66.50M
Cash Equivalents	$48.54M
Revenue	$2.02M
Net Income	$-95.22M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$188.13M
EPS (TTM)	$-0.63
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$172.86M
Sales	$2.02M
Income	$-95.22M
Book/sh	$0.05
Cash/sh	$0.18
Employees	184

Financial Ratios

Quick Ratio	3.02
Current Ratio	3.93
Debt/Eq	572.10

Returns & Margins

ROA	-51.48%
ROE	-409.47%
Operating Margin	-5704.04%

Ownership

Insider Ownership	7.51%
Institutional Ownership	22.26%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.91
P/S	93.32
P/B	13.42

Analyst Data

Recommendation	buy
Target Price	$2.05

Technical Indicators

SMA20	$1.16
SMA50	$0.99
SMA200	$1.18
RSI	14.61
ATR	0.1343

Shares Float	190.57M
Short Float	18.21%
Short Ratio	5.75
Volatility	2.46
Rel Volume	2.29

Performance History

Week	-32.26%
Month	-33.55%
Quarter	-12.13%
6 Months	-37.14%
YTD	-28.44%
Year	-68.43%
3 Years	-78.33%
5 Years	-93.26%
10 Years	-92.78%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-24	$0.70	29,444,660
2026-06-23	$0.70	46,220,900
2026-06-22	$0.84	23,584,600
2026-06-18	$0.92	11,323,200
2026-06-17	$0.97	13,798,500
2026-06-16	$1.03	7,074,000
2026-06-15	$1.07	5,692,700
2026-06-12	$1.05	9,077,100
2026-06-11	$1.08	29,497,500
2026-06-10	$1.34	7,975,000
2026-06-09	$1.39	4,746,700
2026-06-08	$1.38	3,780,500
2026-06-05	$1.35	6,432,900
2026-06-04	$1.49	6,604,200
2026-06-03	$1.40	5,495,600
2026-06-02	$1.39	8,980,300
2026-06-01	$1.45	11,099,800
2026-05-29	$1.30	9,420,700
2026-05-28	$1.28	11,287,100
2026-05-27	$1.15	5,846,300
2026-05-26	$1.11	7,120,900

About Humacyte, Inc.

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

📰 Latest News

Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet

Zacks • 2026-06-19T13:30:02Z

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

Zacks • 2026-06-16T22:00:02Z

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

Zacks • 2026-06-15T16:00:03Z

HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses

Stocktwits • 2026-06-10T22:48:30Z

Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall

MT Newswires • 2026-06-10T20:51:12Z

Humacyte (HUMA) Q1 2025 Earnings Transcript

Motley Fool • 2026-06-01T14:38:43Z

Humacyte (HUMA) Is Up 23.8% After Long-Term Self-Repair Dialysis Data - Has The Bull Case Changed?

Simply Wall St. • 2026-05-31T08:03:01Z

Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization

Insider Monkey • 2026-05-19T11:08:46Z

Humacyte Inc (HUMA) Q1 2026 Earnings Call Highlights: Sales Surge and Strategic Expansions Amid ...

GuruFocus.com • 2026-05-13T23:02:04Z

Humacyte (HUMA) Q1 2026 Earnings Transcript

Motley Fool • 2026-05-13T18:53:15Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$9,702,000	$0	-	-
Cost Of Revenue	$9,702,000	$0	-	-
Total Revenue	$2,038,000	$0	$0	$0
Operating Revenue	$2,038,000	$0	$0	$0
Expenses
Interest Expense	$11,250,000	$9,277,000	$6,599,000	$6,200,000
Total Expenses	$110,175,000	$114,398,000	$100,047,000	$84,578,000
Other Income Expense	$75,967,000	$-29,130,000	$-9,597,000	$76,184,000
Net Non Operating Interest Income Expense	$-8,663,000	$-5,173,000	$-1,132,000	$-3,571,000
Interest Expense Non Operating	$11,250,000	$9,277,000	$6,599,000	$6,200,000
Operating Expense	$100,473,000	$114,398,000	$100,047,000	$84,578,000
General And Administrative Expense	$31,171,000	$25,799,000	$23,497,000	$22,883,000
Other Operating Expenses	-	-	-	$-1,565,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-40,833,000	$-148,701,000	$-110,776,000	$-11,965,000
Net Interest Income	$-8,663,000	$-5,173,000	$-1,132,000	$-3,571,000
Interest Income	$2,587,000	$4,104,000	$5,467,000	$2,629,000
Normalized Income	$-116,800,000	$-119,571,000	$-101,179,000	$-88,149,000
Net Income From Continuing And Discontinued Operation	$-40,833,000	$-148,701,000	$-110,776,000	$-11,965,000
Total Operating Income As Reported	$-108,137,000	$-114,398,000	$-100,047,000	$-84,578,000
Net Income Common Stockholders	$-40,833,000	$-148,701,000	$-110,776,000	$-11,965,000
Net Income	$-40,833,000	$-148,701,000	$-110,776,000	$-11,965,000
Net Income Including Noncontrolling Interests	$-40,833,000	$-148,701,000	$-110,776,000	$-11,965,000
Net Income Continuous Operations	$-40,833,000	$-148,701,000	$-110,776,000	$-11,965,000
Pretax Income	$-40,833,000	$-148,701,000	$-110,776,000	$-11,965,000
Special Income Charges	$37,202,000	$-33,045,000	$-9,337,000	$75,767,000
Interest Income Non Operating	$2,587,000	$4,104,000	$5,467,000	$2,629,000
Operating Income	$-108,137,000	$-114,398,000	$-100,047,000	$-84,578,000
Gross Profit	$-7,664,000	$0	-	-
Per Share
Diluted EPS	$-0.26	$-1.26	$-1.07	$-0.12
Basic EPS	$-0.26	$-1.26	$-1.07	$-0.12
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-98,205,000	$-103,104,000	$-86,861,000	$-73,739,000
Total Unusual Items	$75,967,000	$-29,130,000	$-9,597,000	$76,184,000
Total Unusual Items Excluding Goodwill	$75,967,000	$-29,130,000	$-9,597,000	$76,184,000
Reconciled Depreciation	$7,345,000	$7,190,000	$7,719,000	$8,210,000
EBITDA (Bullshit earnings)	$-22,238,000	$-132,234,000	$-96,458,000	$2,445,000
EBIT	$-29,583,000	$-139,424,000	$-104,177,000	$-5,765,000
Diluted Average Shares	$158,160,468	$118,479,097	$103,420,238	$103,051,366
Basic Average Shares	$158,160,468	$118,479,097	$103,420,238	$103,051,366
Diluted NI Availto Com Stockholders	$-40,833,000	$-148,701,000	$-110,776,000	$-11,965,000
Other Special Charges	$22,267,000	-	$-686,000	-
Restructuring And Mergern Acquisition	$-59,469,000	$33,045,000	$10,023,000	$-75,767,000
Gain On Sale Of Security	$38,765,000	$3,915,000	$-260,000	$417,000
Research And Development	$69,302,000	$88,599,000	$76,550,000	$63,260,000
Selling General And Administration	$31,171,000	$25,799,000	$23,497,000	$22,883,000
Other Gand A	$31,171,000	$25,799,000	$23,497,000	$22,883,000
Salaries And Wages	-	-	$-3,107,000	$0

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$3,109,000	$-52,669,000	$13,546,000	$116,928,000
Total Assets	$116,366,000	$137,872,000	$128,223,000	$204,302,000
Total Non Current Assets	$48,571,000	$90,013,000	$44,945,000	$50,094,000
Other Non Current Assets	$881,000	$51,460,000	$841,000	-
Current Assets	$67,795,000	$47,859,000	$83,278,000	$154,208,000
Other Current Assets	$3,268,000	$2,922,000	$2,830,000	$2,298,000
Inventory	$13,589,000	$0	-	-
Receivables	$441,000	$0	$0	$31,000
Accounts Receivable	$441,000	$0	$0	$31,000
Cash Cash Equivalents And Short Term Investments	$50,497,000	$44,937,000	$80,448,000	$151,879,000
Cash And Cash Equivalents	$50,497,000	$44,937,000	$80,448,000	$149,772,000
Prepaid Assets	-	-	-	-
Debt
Total Debt	$64,846,000	$16,537,000	$18,853,000	$50,066,000
Long Term Debt And Capital Lease Obligation	$62,418,000	$13,620,000	$16,293,000	$39,189,000
Long Term Debt	$35,444,000	-	$38,600,000	$20,336,000
Current Debt And Capital Lease Obligation	$2,428,000	$2,917,000	$2,560,000	$10,877,000
Current Debt	-	-	-	$8,571,000
Other Current Borrowings	-	-	-	$8,571,000
Liabilities
Total Liabilities Net Minority Interest	$113,257,000	$190,541,000	$114,677,000	$87,374,000
Total Non Current Liabilities Net Minority Interest	$94,885,000	$170,587,000	$96,234,000	$67,794,000
Other Non Current Liabilities	$13,075,000	$135,298,000	$77,227,000	$28,605,000
Derivative Product Liabilities	$19,392,000	$21,669,000	$2,714,000	$0
Current Liabilities	$18,372,000	$19,954,000	$18,443,000	$19,580,000
Payables And Accrued Expenses	$9,311,000	$9,672,000	$10,592,000	$4,476,000
Payables	$5,404,000	$4,490,000	$6,490,000	$1,595,000
Accounts Payable	$5,404,000	$4,490,000	$6,490,000	$1,595,000
Other Current Liabilities	-	$1,123,000	$53,000	-
Current Deferred Liabilities	-	-	-	$0
Current Deferred Taxes Liabilities	-	-	-	$0
Non Current Deferred Liabilities	-	-	-	-
Non Current Deferred Taxes Liabilities	-	-	-	-
Equity
Common Stock Equity	$3,109,000	$-52,669,000	$13,546,000	$116,928,000
Total Equity Gross Minority Interest	$3,109,000	$-52,669,000	$13,546,000	$116,928,000
Stockholders Equity	$3,109,000	$-52,669,000	$13,546,000	$116,928,000
Retained Earnings	$-726,848,000	$-686,015,000	$-537,314,000	$-426,538,000
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$193,000,611	$130,027,509	$103,673,728	$103,229,013
Share Issued	$193,000,611	$130,027,509	$103,673,728	$103,229,013
Tangible Book Value	$3,109,000	$-52,669,000	$13,546,000	$116,928,000
Invested Capital	$38,553,000	$-52,669,000	$13,546,000	$145,835,000
Working Capital	$49,423,000	$27,905,000	$64,835,000	$134,628,000
Capital Lease Obligations	$29,402,000	$16,537,000	$18,853,000	$21,159,000
Total Capitalization	$38,553,000	$-52,669,000	$13,546,000	$137,264,000
Additional Paid In Capital	$729,937,000	$633,333,000	$550,850,000	$543,456,000
Capital Stock	$20,000	$13,000	$10,000	$10,000
Common Stock	$20,000	$13,000	$10,000	$10,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$26,974,000	$13,620,000	$16,293,000	$18,853,000
Current Capital Lease Obligation	$2,428,000	$2,917,000	$2,560,000	$2,306,000
Pensionand Other Post Retirement Benefit Plans Current	$6,633,000	$6,242,000	$5,238,000	$4,227,000
Current Accrued Expenses	$3,907,000	$5,182,000	$4,102,000	$2,881,000
Net PPE	$47,690,000	$38,553,000	$44,104,000	$50,094,000
Accumulated Depreciation	$-41,332,000	$-36,087,000	$-31,326,000	$-26,181,000
Gross PPE	$89,022,000	$74,640,000	$75,430,000	$76,275,000
Leases	$27,967,000	$27,901,000	$27,844,000	$26,355,000
Other Properties	$58,861,000	$44,549,000	$45,713,000	$47,876,000
Machinery Furniture Equipment	$2,194,000	$2,190,000	$1,873,000	$1,364,000
Properties	$0	$0	$0	$0
Inventories Adjustments Allowances	$-8,897,000	$0	-	-
Finished Goods	$10,122,000	$0	-	-
Work In Process	$6,541,000	$0	-	-
Raw Materials	$5,823,000	$0	-	-
Construction In Progress	-	-	$0	$680,000
Other Short Term Investments	-	-	$0	$2,107,000

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-105,926,000	$-99,694,000	$-75,585,000	$-72,177,000
Operating Activities
Operating Cash Flow	$-105,042,000	$-98,122,000	$-73,305,000	$-71,129,000
Cash Flow From Continuing Operating Activities	$-105,042,000	$-98,122,000	$-73,305,000	$-71,129,000
Operating Gains Losses	$-16,493,000	$-3,911,000	$2,699,000	$-411,000
Investing Activities
Capital Expenditure	$-884,000	$-1,572,000	$-2,280,000	$-1,048,000
Investing Cash Flow	$-884,000	$-1,572,000	$-173,000	$4,845,000
Cash Flow From Continuing Investing Activities	$-884,000	$-1,572,000	$-173,000	$4,845,000
Financing Activities
Issuance Of Capital Stock	$103,450,000	$89,052,000	$0	-
Financing Cash Flow	$61,486,000	$114,183,000	$4,507,000	$-1,446,000
Cash Flow From Continuing Financing Activities	$61,486,000	$114,183,000	$4,507,000	$-1,446,000
Net Other Financing Charges	$-88,939,000	$19,390,000	$38,007,000	-
Cash Dividends Paid	$0	$0	-	-
Net Preferred Stock Issuance	$56,450,000	$43,126,000	$0	-
Preferred Stock Issuance	$56,450,000	$43,126,000	$0	-
Net Common Stock Issuance	$47,000,000	$45,926,000	$0	-
Common Stock Issuance	$47,000,000	$45,926,000	$0	-
Other
Repayment Of Debt	$-2,754,000	$-2,579,000	$-34,066,000	$-1,981,000
Issuance Of Debt	$39,783,000	$0	-	$0
End Cash Position	$50,850,000	$95,290,000	$80,801,000	$149,772,000
Beginning Cash Position	$95,290,000	$80,801,000	$149,772,000	$217,502,000
Changes In Cash	$-44,440,000	$14,489,000	$-68,971,000	$-67,730,000
Interest Paid Cff	$-45,000	$0	-	-
Proceeds From Stock Option Exercised	$9,991,000	$8,320,000	$566,000	$535,000
Net Issuance Payments Of Debt	$37,029,000	$-2,579,000	$-34,066,000	$-1,981,000
Net Long Term Debt Issuance	$37,029,000	$-2,579,000	$-34,066,000	$-1,981,000
Long Term Debt Payments	$-2,754,000	$-2,579,000	$-34,066,000	$-1,981,000
Long Term Debt Issuance	$39,783,000	$0	-	$0
Net PPE Purchase And Sale	$-884,000	$-1,572,000	$-2,280,000	$-1,048,000
Purchase Of PPE	$-884,000	$-1,572,000	$-2,280,000	$-1,048,000
Change In Working Capital	$-23,395,000	$311,000	$6,571,000	$1,029,000
Change In Other Current Liabilities	$-44,000	$-53,000	$-50,000	$-45,000
Change In Payables And Accrued Expense	$-736,000	$276,000	$6,978,000	$-262,000
Change In Accrued Expense	$-1,709,000	$2,238,000	$2,167,000	$247,000
Change In Payable	$973,000	$-1,962,000	$4,811,000	$-509,000
Change In Account Payable	$973,000	$-1,962,000	$4,811,000	$-509,000
Change In Prepaid Assets	$-527,000	$88,000	$-388,000	$1,364,000
Change In Inventory	$-21,827,000	$0	-	-
Change In Receivables	$-261,000	$0	$31,000	$145,000
Changes In Account Receivables	$-261,000	$0	$31,000	$145,000
Other Non Cash Items	$-50,316,000	$40,852,000	$13,654,000	$-74,176,000
Stock Based Compensation	$9,753,000	$6,137,000	$6,828,000	$6,184,000
Provisionand Write Offof Assets	$8,897,000	$0	-	-
Depreciation Amortization Depletion	$7,345,000	$7,190,000	$7,719,000	$8,210,000
Depreciation And Amortization	$7,345,000	$7,190,000	$7,719,000	$8,210,000
Amortization Cash Flow	$2,017,000	$2,086,000	$2,060,000	$2,059,000
Amortization Of Intangibles	$2,017,000	$2,086,000	$2,060,000	$2,059,000
Depreciation	$5,328,000	$5,104,000	$5,659,000	$6,151,000
Gain Loss On Investment Securities	$-38,765,000	$-3,915,000	$260,000	$-417,000
Gain Loss On Sale Of PPE	$5,000	$4,000	$18,000	$6,000
Net Income From Continuing Operations	$-40,833,000	$-148,701,000	$-110,776,000	$-11,965,000
Interest Paid Supplemental Data	-	$0	$1,613,000	$2,668,000
Net Investment Purchase And Sale	-	$0	$2,107,000	$5,893,000
Sale Of Investment	-	$0	$2,107,000	$16,000,000
Purchase Of Investment	-	-	$0	$-10,107,000
Change In Other Working Capital	-	-	-	$-173,000
Asset Impairment Charge	-	-	-	$0
Sale Of PPE	-	-	-	-

Fetched: 2026-06-22